PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate
- Conditions
- Advanced Breast Cancer Female
- Interventions
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2022-01-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 131
- Registration Number
- NCT02600923
- Locations
- 🇧🇷
Hospital Sao Lucas da PUCRS / Uniao Brasileira de Educacao e Assistencia, Porto Alegre, RIO Grande DO SUL, Brazil
🇦🇷Instituto de Cardiologia y Cirugia Cardiovascular, Santa Fe, Argentina
🇧🇷Hospital Da Cidade De Passo Fundo, Passo Fundo, RIO Grande DO SUL, Brazil
Food Effect Study PF-04136309
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2018-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT02598206
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
Efficacy Study Of Tofacitinib In Pediatric JIA Population
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Drug: CP-690,550 (tofacitinib)Other: placebo
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 225
- Registration Number
- NCT02592434
- Locations
- 🇺🇸
Pediatric Specialty Team Centers of LLU Children's Hospital, Loma Linda, California, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Connecticut Children's Medical Center, Hartford, Connecticut, United States
Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 43
- Registration Number
- NCT02584634
- Locations
- 🇺🇸
Ophthalmic Consultants of Boston Inc (OCB), Boston, Massachusetts, United States
🇯🇵Aichi cancer center central hospital, Nagoya, Aichi, Japan
🇪🇸Hospital Universitari de la Vall d'Hebron, Barcelona, Spain
A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)
- Conditions
- Ovarian Cancer
- Interventions
- Drug: PLDBiological: avelumab
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 566
- Registration Number
- NCT02580058
- Locations
- 🇺🇸
Maryland Oncology Hematology, P.A., Columbia, Maryland, United States
🇺🇸Texas Oncology - The Woodlands, Gynecologic Oncology, The Woodlands, Texas, United States
🇬🇷General Hospital of Athens Alexandra, Athens, Greece
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
- Conditions
- Part 1MELANOMASCCHNSARCOMAOVCAOTHER SOLID TUMORSPart 1 and 2NSCLCUROTHELIAL CARCINOMA
- Interventions
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 147
- Registration Number
- NCT02573259
- Locations
- 🇺🇦
Communal Non-profit Institution "City Clinical Hospital #4" of Dnipro City Council, Department of, Dnipro, Ukraine
🇺🇸University of Rochester, Rochester, New York, United States
🇺🇸Tennessee Oncology, PLLC, Smyrna, Tennessee, United States
A Study of PF-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects
- Conditions
- Healthy Subjects
- Interventions
- Device: PF-06410293 PFSDevice: PF-06410293 PFP
- First Posted Date
- 2015-10-08
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 164
- Registration Number
- NCT02572245
- Locations
- 🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States
The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis
- Conditions
- Chronic Plaque Psoriasis
- Interventions
- Behavioral: QUESTIONNAIRE ON SMOKING HABITS
- First Posted Date
- 2015-10-07
- Last Posted Date
- 2018-12-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 183
- Registration Number
- NCT02570750
- Locations
- 🇷🇴
County Emergency Hospital Zalau / Dermatology Department, Zalau, Salaj, Romania
🇷🇴County Hospital Targoviste / Dermatology Department, Targoviste, Dambovita, Romania
🇷🇴County Emergency Hospital "Saint Pantelimon" Focsani / Dermatology Department, Focsani, Vrancea, Romania
PPI And Food Effect Study For PF-06463922 In Healthy Volunteers
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 27
- Registration Number
- NCT02569554
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT02565628
- Locations
- 🇺🇸
MD Clinical, Hallandale Beach, Florida, United States
🇺🇸QPS-MRA, LLC (MRA Clinical Research), South Miami, Florida, United States
🇺🇸Qps-Mra Llc, South Miami, Florida, United States